Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.
Adult
Aged
Aldosterone
/ pharmacology
Biomarkers
/ metabolism
Case-Control Studies
Female
Fibrosis
/ metabolism
Follow-Up Studies
Gitelman Syndrome
/ drug therapy
Humans
Hypertension
/ drug therapy
Inflammation
/ metabolism
Inflammation Mediators
/ metabolism
Leukocytes, Mononuclear
/ metabolism
Male
Middle Aged
Myosin-Light-Chain Phosphatase
/ metabolism
NADPH Oxidases
/ metabolism
Phosphorylation
Prognosis
Signal Transduction
Young Adult
Aldosterone
Angiotensin II
Gitelman’s syndrome
Mononuclear leucocytes
Oxidative stress
Rho kinase
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
28
03
2018
accepted:
09
08
2018
pubmed:
24
8
2018
medline:
21
8
2019
entrez:
24
8
2018
Statut:
ppublish
Résumé
Aldosterone proinflammatory/profibrotic effects are mediated by the induction of mononuclear leucocytes (MNL) to express oxidative stress (OxSt)-related proteins, such as p22 p22 At basal condition, p22 GS patients seem to be protected by the OxSt status induced by aldosterone and revealed in HS. This human model could provide additional clues to highlight the proinflammatory/cardiovascular remodeling effects of aldosterone.
Identifiants
pubmed: 30136149
doi: 10.1007/s40618-018-0942-9
pii: 10.1007/s40618-018-0942-9
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Aldosterone
4964P6T9RB
NADPH Oxidases
EC 1.6.3.-
CYBA protein, human
EC 1.6.3.1
Myosin-Light-Chain Phosphatase
EC 3.1.3.53
PPP1R12A protein, human
EC 3.1.3.53
Types de publication
Journal Article
Langues
eng
Pagination
521-526Références
J Am Soc Nephrol. 2002 Apr;13(4):836-47
pubmed: 11912242
Curr Hypertens Rep. 2003 Feb;5(1):59-65
pubmed: 12530937
Curr Hypertens Rep. 2003 Feb;5(1):66-72
pubmed: 12530938
Curr Hypertens Rep. 2003 Apr;5(2):122-5
pubmed: 12642011
N Engl J Med. 2003 Apr 3;348(14):1309-21
pubmed: 12668699
J Cardiovasc Pharmacol. 2003 Jun;41(6):955-63
pubmed: 12775976
Physiol Rev. 2003 Oct;83(4):1325-58
pubmed: 14506307
Circulation. 2003 Oct 28;108(17):2034-40
pubmed: 14581381
J Clin Endocrinol Metab. 2004 Apr;89(4):1973-6
pubmed: 15070972
Hypertension. 2005 Aug;46(2):313-20
pubmed: 15998706
Am J Physiol Cell Physiol. 2007 Jan;292(1):C82-97
pubmed: 16870827
J Hypertens. 2007 Feb;25(2):259-64
pubmed: 17211228
Nephrol Dial Transplant. 2008 Sep;23(9):2804-9
pubmed: 18344243
Curr Pharm Des. 2008;14(35):3749-57
pubmed: 19128227
J Hypertens. 2010 Jan;28(1):111-8
pubmed: 19797979
Hypertension. 2012 Aug;60(2):e9
pubmed: 22733466
J Clin Endocrinol Metab. 2013 Jun;98(6):2494-501
pubmed: 23539731
J Hypertens. 2014 Feb;32(2):331-8
pubmed: 24356540
Expert Opin Pharmacother. 2014 May;15(7):909-12
pubmed: 24617854
J Hypertens. 2014 Nov;32(11):2109-19; discussion 2119
pubmed: 25202962
J Endocrinol Invest. 2015 Jul;38(7):711-6
pubmed: 25740064
High Blood Press Cardiovasc Prev. 2015 Sep;22(3):215-23
pubmed: 25759028
Free Radic Biol Med. 2015 Nov;88(Pt A):51-8
pubmed: 25770663
Am J Transl Res. 2016 Feb 15;8(2):314-28
pubmed: 27158328
Am J Physiol. 1989 Aug;257(2 Pt 1):E170-4
pubmed: 2764099
Kidney Int. 2017 Jan;91(1):24-33
pubmed: 28003083
J Clin Hypertens (Greenwich). 2017 Nov;19(11):1060-1062
pubmed: 28834202
Am J Physiol. 1987 Apr;252(4 Pt 1):E505-8
pubmed: 2952017
Am J Physiol. 1985 Mar;248(3 Pt 1):E388-90
pubmed: 3156509
Steroids. 1994 Feb;59(2):160-3
pubmed: 8191547